Advanced search
Publication Cover
Scandinavian Journal of Urology Volume 54, 2020 - Issue 2
Journal homepage
1,187
Views
2
CrossRef citations to date
0
Altmetric
Articles

Non-metastatic prostate cancer: rationale for conservative treatment and impact on disease-related morbidity and mortality in the elderly

Sven LöffelerSection of Urology, Vestfold Hospital Trust, Tønsberg, Norway; ;Department of Clinical Medicine, University of Bergen, Bergen, Norway; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-3553-2491View further author information
ORCID Icon,
Adrian HallandSection of Urology, Vestfold Hospital Trust, Tønsberg, Norway; View further author information
,
Haris FawadInstitute of Population-Based Cancer Research, Cancer Registry of Norway, Oslo, Norway; View further author information
,
Christian BeislandDepartment of Clinical Medicine, University of Bergen, Bergen, Norway; ;Department of Urology, Haukeland University Hospital, Bergen, NorwayORCID Iconhttp://orcid.org/0000-0002-3216-4937View further author information
ORCID Icon &
Erik S. HaugSection of Urology, Vestfold Hospital Trust, Tønsberg, Norway; View further author information
Pages 105-109 | Received 13 Nov 2019, Accepted 17 Feb 2020, Published online: 05 Mar 2020

References

  • Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71(4):618–629.
  • Bill-Axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med. 2014;370(10):932–942.
  • Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. The Lancet. 2002;360(9327):103–108.
  • Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. 2009;373(9660):301–308.
  • Loffeler S, Halland A, Weedon-Fekjaer H, et al. High Norwegian prostate cancer mortality: evidence of over-reporting. Scand J Urol. 2018;52:122–128.
  • Pettersson A, Robinson D, Garmo H, et al. Age at diagnosis and prostate cancer treatment and prognosis: a population-based cohort study. Ann Oncol. 2018;29(2):377–385.
  • Mottet N, van den Bergh RCN, Briers E, et al. EAU guidelines on prostate cancer. Arnhem the Netherlands: European Association of Urology; 2019.
  • Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649–655.
  • Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
  • King JC, Zenati M, Steve J, et al. Deviations from expected treatment of pancreatic cancer in octogenarians: analysis of patient and surgeon factors. Ann Surg Oncol. 2016;23(13):4149–4155.
  • Owonikoko TK, Ragin CC, Belani CP, et al. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. JCO. 2007;25(35):5570–5577.
  • Rauh-Hain JA, Pepin KJ, Meyer LA, et al. Management for elderly women with advanced-stage, high-grade endometrial cancer. Obstet Gynecol. 2015;126(6):1198–1206.
  • Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol. 2008;53(1):68–80.
  • Årsrapport 2017. med resultater og forbedringstiltak fra Nasjonalt kvalitetsregister for prostatakreft. Oslo: Kreftregisteret (Norwegian Cancer Registry); 2018.
  • Lu-Yao GL, Albertsen PC, Moore DF, et al. Fifteen-year outcomes following conservative management among men aged 65 years or older with localized prostate cancer. Eur Urol. 2015;68(5):805–811.
  • Akre O, Garmo H, Adolfsson J, et al. Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden. Eur Urol. 2011;60(3):554–563.
  • Bratt O, Folkvaljon Y, Hjalm Eriksson M, et al. Undertreatment of men in their seventies with high-risk nonmetastatic prostate cancer. Eur Urol. 2015;68(1):53–58.
  • Sheng W, Kirschner-Hermanns R, Zhang H. Elderly patients aged ≥ 75 years with locally advanced prostate cancer may benefit from local treatment: a population-based propensity score-adjusted analysis. World J Urol. 2018;37:317–325.
  • Yang DD, Mahal BA, Muralidhar V, et al. Receipt of definitive therapy in elderly patients with unfavorable-risk prostate cancer. Cancer. 2017;123(24):4832–4840.
  • Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424–433.
  • Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138–148.
  • Wilt TJ, Jones KM, Barry MJ, et al. Follow-up of prostatectomy versus observation for early prostate cancer. N Engl J Med. 2017;377(2):132–142.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.